Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis / Guglielmelli, P., Barosi, G., Rambaldi, A., Marchioli, R., Masciulli, A., Tozzi, L., Biamonte, F., Bartalucci, N., Gattoni, E., Lupo, M.L., Finazzi, G., Pancrazzi, A., Antonioli, E., Susini, M.C., Pieri, L., Malevolti, E., Usala, E., Occhini, U., Grossi, A., Caglio, S., et al.. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 118:(2011), pp. 2069-2076. [10.1182/blood-2011-01-330563]
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
GUGLIELMELLI, PAOLA;TOZZI, LORENZO;BIAMONTE, FLAVIA;BARTALUCCI, NICCOLO';PANCRAZZI, ALESSANDRO;ANTONIOLI, ELISABETTA;SUSINI, MARIA CHIARA;PIERI, LISA;MALEVOLTI, ELISA;BOSI, ALBERTO;VANNUCCHI, ALESSANDRO MARIA
2011
Abstract
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
GuglielmelliBLOOD_RAD001.full.pdf
Accesso chiuso
Descrizione: Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
317.3 kB
Formato
Adobe PDF
|
317.3 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
